Drug interactions
Dabrafenib + Metformin-repaglinide
Severity: Moderate
Dabrafenib and Metformin-repaglinide: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Dabrafenib induces CYP3A4 and CYP2C8, which can lower repaglinide exposure and weaken its glucose-lowering effect. Dabrafenib can also cause hyperglycemia, which may worsen diabetes control.
What this interaction means in plain words
Dabrafenib and Metformin-repaglinide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Dabrafenib belongs to Oncology; Metformin-repaglinide belongs to Endocrine.
Why it happens
Induction of CYP3A4 and CYP2C8 by dabrafenib increases repaglinide clearance, and dabrafenib has its own hyperglycemic effect.
What to do
Monitor blood glucose frequently during dabrafenib therapy and increase the repaglinide dose or alter therapy if control worsens. Reassess doses after dabrafenib is stopped.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Dabrafenib and Metformin-repaglinide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Metformin-repaglinide
Other interactions of Dabrafenib
Frequently asked questions
Can I take Dabrafenib with Metformin-repaglinide?
MediHelp rates the interaction as moderate. Dabrafenib and Metformin-repaglinide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Dabrafenib induces CYP3A4 and CYP2C8, which can lower repaglinide exposure and weaken its glucose-lowering effect. Dabrafenib can also cause hyperglycemia, which may worsen diabetes control.
How serious is the interaction between Dabrafenib and Metformin-repaglinide?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood glucose frequently during dabrafenib therapy and increase the repaglinide dose or alter therapy if control worsens. Reassess doses after dabrafenib is stopped.
What other medicines interact with Metformin-repaglinide?
MediHelp also lists interactions of Metformin-repaglinide with, for example, Gemfibrozil, Apalutamide, Clarithromycin. The full list is on the Metformin-repaglinide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
